Currently, CD8+ T-cell infiltration and expression of PD-L1 are being considered as biomarkers to select the population of NSCLC patients that are most likely to respond to checkpoint antibody therapy [42]. This evidence concerns the gene CD8A and non-small cell lung carcinoma.